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The Nevada State Health Division (NSHD),
with assistance from the Centers for Disease
Control and Prevention (CDC), conducted a
study to identify environmental exposures in
the Churchill County community where 15
cases of childhood leukemia,14 of which were
acute lymphoblastic leukemia (ALL), had been
diagnosed between 1997 and 2002. State
health ofﬁcials estimated that fewer than 2 cases
would have been expected (Steinmaus et al.
2004). The detailed methods, results, and rec-
ommendations of this investigation have been
documented by Rubin et al. (2007) in this
mini-monograph. 
Although the investigation found higher
levels of potentially toxic substances, including
tungsten, arsenic, and the dichlorodiphenyl-
trichloroethane (DDT) metabolite dichloro-
diphenyldichloroethylene (DDE) in residents
of Churchill County than the values reported
in the National Report on Human Exposure
to Environmental Chemicals (CDC 2003b),
case and comparison families had similar body
burdens of these contaminants. Because the
two groups had similar concentrations, CDC,
in collaboration with Mary Relling of St. Jude
Children’s Research Hospital and with the
advice of William Carroll, Head of the
Children’s Oncology Group (COG) Acute
Leukemia Disease Committee, conducted
genetic studies in an effort to identify gene
variants that might have made case children
more susceptible than comparison children to
adverse effects of the exposures documented in
Churchill County. As a result of the high levels
of tungsten found in residents of Churchill
County, the investigation also included a study
to identify variant forms of three genes that
code for enzymes that are inhibited by tung-
sten and may, as a result, affect DNA syn-
thesis, hematopoiesis, or detoxification of
contaminants. For a review of current knowl-
edge of tungsten, including environmental
chemistry, toxicologic properties, and ongoing
investigation into its possible toxicity, see
Koutsospyros et al. (2006).
We also attempted to determine whether
the frequency and types of cytogenetic aberra-
tions found in bone marrow specimens from
case children were consistent with the fre-
quency of these abnormalities found in the
general population of children with ALL
enrolled in COG protocols or whether dif-
ferences in these aberrations provided infor-
mation that would suggest a common
environmental exposure. The following is a
report of results of genetic studies conducted
on specimens in the Churchill County case–
control study.
Materials and Methods
Study participants. We enrolled a total of 205
participants representing 14 (of the 15 eligible)
case families and 55 comparison families and
asked them to complete mailed questionnaires,
participate in personal interviews, and donate
biological specimens. We excluded 1 of the 14
cases from the analysis because the child lived
in the target area for only a short time before
diagnosis. The family of another child declined
to participate. A third case was excluded
because the diagnosis was acute myelogenous
leukemia rather than ALL, leaving 11 case chil-
dren for our analyses. Community-based refer-
ence children were matched to case children
on the basis of year of birth and sex. The origi-
nal goal to match four community-based refer-
ence children to each case child was not always
achieved. Data from 42 comparison children
matched to these 11 case children are also
included in our analyses. Twenty parents of
case children also provided genetic data. Data
from the 2 additional cases excluded from our
analysis (because of residency and diagnosis)
and the 6 control children matched to them
were included in single nucleotide polymor-
phism (SNP, pronounced “snip”) discovery.
Blood and cheek-swab specimens were col-
lected for DNA extraction. The study protocol
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OBJECTIVE: In a study to identify exposures associated with 15 cases of childhood leukemia, we
found levels of tungsten, arsenic, and dichlorodiphenyldichloroethylene in participants to be higher
than mean values reported in the National Report on Human Exposure to Environmental
Chemicals. Because case and comparison families had similar levels of these contaminants, we con-
ducted genetic studies to identify gene polymorphisms that might have made case children more
susceptible than comparison children to effects of the exposures.
DESIGN: We compared case with comparison children to determine whether differences existed in
the frequency of polymorphic genes, including genes that code for enzymes in the folate and purine
pathways. We also included discovery of polymorphic forms of genes that code for enzymes that are
inhibited by tungsten: xanthine dehydrogenase, sulﬁte oxidase (SUOX gene), and aldehyde oxidase. 
PARTICIPANTS: Eleven case children were age- and sex-matched with 42 community comparison
children for genetic analyses. Twenty parents of case children also contributed to the analyses. 
RESULTS: One bilalleleic gene locus in SUOX was signiﬁcantly associated with either case or compari-
son status, depending on which alleles the child carried (without adjusting for multiple comparisons). 
CONCLUSIONS: Although genetic studies did not provide evidence that a common agent or genetic
susceptibility factor caused the leukemias, the association between a SUOX gene locus and disease
status in the presence of high tungsten and arsenic levels warrants further investigation.
RELEVANCE: Although analyses of community clusters of cancer have rarely identiﬁed causes, these
ﬁndings have generated hypotheses to be tested in subsequent studies. 
KEY WORDS: arsenic, children, cluster, DDE, enzymes, genetics, leukemia, polymorphism, tungsten.
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[Online 30 November 2006]and procedures for written informed consent
and assent were reviewed and approved by the
CDC Institutional Review Board (IRB; proto-
col 3195; CDC 2003a) and complied with all
applicable requirements of the U.S. regula-
tions. All adult participants signed IRB-
approved, written informed consent. Children
7 years of age and older signed written assents,
and the parents or legal guardians of children
younger than 7 years signed written consents.
Genetic studies. Two types of genetic infor-
mation were assessed in this case-comparison
study: a) We collected and assessed all avail-
able information about the gene or chromoso-
mal abnormalities characteristic of a child’s
leukemia cells that were ascertained at case
presentation from bone marrow specimens
and used for diagnosis and classification of
leukemia. These abnormalities include chro-
mosomal aberrations such as translocations
and abnormal numbers of chromosomes (e.g.,
hyperdiploidy) and gene mutations (Table 1).
b) We also assessed inherited genetic variation
that may affect susceptibility to leukemia in
people exposed to environmental leuke-
mogenic agents (Pui et al. 2004; Smith et al.
2005). This variation includes polymorphisms
in genes that code for proteins involved in
metabolism of drugs and environmental toxi-
cants, in synthesis of DNA, in innate immu-
nity, and other enzymes. The most abundant
type of polymorphism is a SNP. A locus refers
to a particular base pair in the genome. If
there is genetic variability at a locus, each vari-
ant is referred to as an allele. A person inherits
two alleles, one from each parent, at each
autosomal locus. All loci in this study were bi-
allelic; the majority were SNPs, although one
was a deletion and one was a variable number
of tandem repeats polymorphism (VNTR)
with two alleles.
We genotyped case and comparison fami-
lies for genes that code for proteins that may
affect, or be affected by, elevated concentra-
tions of tungsten, arsenic, pesticide metabo-
lites, or other environmental agents. All gene
names, gene symbols, and their accession num-
bers are from GenBank (http://www.ncbi.nlm.
nih.gov/Genbank/). The 13 genes that we
focused on include genes in the folate/purine
biosynthesis pathway: methylene tetrahydrofo-
late reductase (MTHFR, GenBank accession
no. AY338232), serine hydroxymethyltrans-
ferase 1 (SHMT1; GenBank accession no.
AK223552), reduced folate carrier (SLC19A1;
GenBank accession no. BC003068), thiop-
urine S-methyltransferase (TPMT; GenBank
accession no. BC009596), and thymidylate
synthetase (TYMS; GenBank accession no.
BC083512). We also examined genes involved
in xenobiotic metabolism including ATP-bind-
ing cassette, subfamily B (ABCB1; GenBank
accession no. AY910577), glutathione S-trans-
ferase pi (GSTP1; GenBank accession no.
BT019950), and NAD(P)H dehydrogenase,
quinone 1 (NQO1; GenBank accession no.
BC007659). In addition, we genotyped poly-
morphisms in the vitamin D receptor gene
(VDR; GenBank accession no. AB002168),
which plays a role in cell differentiation, and
the gene coding for mannose-binding lectin
(protein C) 2 (MBL2; GenBank accession no.
BC096181), an important mediator compo-
nent of the innateimmune defense system.
We also performed SNP discovery in
three genes that code for enzymes inhibited
by tungsten [xanthine dehydrogenase
(XDH; EC1.1.1.204, National Center for
Biotechnology Information (NCBI) geneID:
7498, GenBank accession no. NM_000379.3),
aldehyde oxidase (AOX1; EC1.2.3.11; proba-
bly identical to retinaldehyde oxidase,
EC1.2.3.1, NCBI geneID: 316, GenBank
accession no. NM_001159.3), and sulﬁte oxi-
dase (SUOX; EC1.8.3.1, NCBI geneID: 6821,
GenBank accession no. NM_000456.2)], using
specimens from 11 case children and 24
matched comparison children. The comparison
children were selected by randomly sampling
two (or in two instances, three) of the compari-
son children matched to each case child. In
addition, to characterize variation in these genes
as a resource for future studies, we also included
in our SNP discovery 52 specimens from the
Human Variation Panels of the Human
Genetic Cell Repository (sponsored by the
National Institute of General Medical Sciences
and deposited with the Coriell Institute for
Medical Research). Briefly, amplification
primers were designed, and an amplicon tiling
model spanning both coding and regulatory
regions was developed. Polymerase chain reac-
tion (PCR) amplicons covering all intron/exon
borders, full exon sequences, known promoter
sequences, and 3´ untranslated regions (UTRs)
of each of the three genes were ampliﬁed, and
amplicons were sequenced bidirectionally using
Big Dye version 3.1 (Applied Biosystems,
Foster City, CA) terminator chemistry in con-
junction with ABI 3700 /3730xl DNA analyz-
ers (Applied Biosystems). For these three genes,
we used computer modeling with the freely
available programs PolyPhen (http://genetics.
bwh.harvard.edu/pph/; Ramensky et al. 2002)
and SIFT (sorting intolerant from tolerant)
(http://blocks.fhcrc.org/sift/SIFT.html; Ng and
Henikoff 2001) to predict which SNPs would
cause functional changes in the proteins for
which the genes coded.
The polymorphisms and their dbSNP
(Single Nucleotide Polymorphism database;
http://www.ncbi.nlm.nih.gov/SNP/) identiﬁer,
if available, are listed below. Polymorphisms in
TYMS 28-bp tandem repeat and TPMT vari-
ants 460G→A (rs1800460) and 719A→G
(rs28933403) were genotyped as described by
Relling et al. (2004). We genotyped SLC19A1
80A→G polymorphism (rs1051266) by direct
sequencing, using primers AGTGTCAC
CTTCGTCCCCTC (forward and sequenc-
ing) and CTCCCGCGTGAAGTTCTT
(reverse). We genotyped the SHMT1
1420C→T polymorphism (rs1979277) by a
modification of a Taqman assay (http://
snp500cancer.nci.nih.gov; SNP500 assay
number 003_1859), using amplification
primers ATTTGTGAAGAAAACATGAA
AAA (forward) and AGACTGGCAGGG
GATAAGTA (reverse). The GSTP1 313A→G
(rs1695), NQO1 609C→T (rs1800566),
MBL2 codon 54A→G (rs1800450), ABCB1
3435C→T (rs1045642), MTHFR 677C→T
(rs1801133), and VDR start codon FokI poly-
morphism (rs2228570) were genotyped by
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Table 1. Eleven cases of ALL in Churchill County, Nevada, by age group, diagnosis, WBC count, and
cytogenetic studies.
Age group at 
diagnosis (years)  Diagnosis WBC count Cytogenetic results
12–20 Precursor B-cell ALL 63,700 No marrow stored
12–20 T-cell ALL 84,000 Metaphase cells show male karyotype with no clonal 
abnormality reported
2–10 Precursor B-cell ALL 6,800 Metaphase cells show normal male karyotype on GTG banding
2–10 Precursor B-cell ALL 216,500 Cells did not divide for metaphase analysis
2–10 Precursor B-cell ALL 3,900 Metaphase cells show male karyotype with no clonal 
abnormality reported
2–10 Precursor B-cell ALL 2,400 Metaphase cells show normal male karyotype
2–10 Precursor B-cell ALL 7,200 Abnormal karyotype consistent with ALL. T (12; 21) TEL-AML1 
positive; MLL negative; E2A-PBX negative, BCR-ABL negative. 
Chromosome 12p aberration in association with chromosome 
13q aberration
2–10 Precursor B-cell ALL 9,800 Metaphase cells show male karyotype with no clonal 
abnormality reported
2–10 Precursor B-cell ALL 2,600 Metaphase cells show abnormal female karyotype.
Hyperdiploid clone in ~75% of cells
2–10 Precursor B-cell ALL Pancytopenia TEL-AML1 positive; MLL negative; E22A-PBX-1 negative; 
BCR-ABL negative
2–10  Precursor B-cell ALL Not obtained Not obtained
WBC, white blood cell.
Note: When translocations are not reported, neither the reverse-transcriptase polymerase chain reaction nor fluores-
cence in situ hybridization was done.DNAPrint Genomics (Sarasota, FL) in a multi-
plex PCR followed by single base extension. 
Statistical analysis. We performed a (uni-
variate) matched logistic regression analysis
using data from each locus listed in Tables 2
and 3. Note that all loci are bi-allelic. For all
analyses, we used a co-dominant model that
treated the number of minor alleles at the locus
of interest as the risk factor. For each locus, the
“minor” allele is the less common allele. We
calculated point estimates, 95% (exact) conﬁ-
dence intervals (CIs) and (exact) p-values using
SAS PROCLOGISTIC (version 9.3.1; SAS
Institute Inc., Cary, NC). Analyses of AOX1,
SUOX, and XDH included data from 11 case
children and 24 comparison children matched
with the case children who were included in
the SNP discovery. Analyses of all other loci
included data from 11 case children and 42
matched comparison children.
For loci in AOX1, SUOX, and XDH, we
also considered variables that summarize the
effect of several loci. Speciﬁcally, we compared
the ratio of minor alleles with the total number
of alleles genotyped between case children and
comparison participants. A “minor” allele was
declared “rare” if there were two or fewer copies
of that allele observed in the Churchill County
study population, and a locus was called a rare-
allele locus if the minor allele was rare. We also
compared the ratio of rare alleles with the total
number of alleles at rare-allele loci genotyped
between case children and comparison partici-
pants. Finally, we compared case and compari-
son participants’ potentially deleterious alleles
(as determined by PolyPhen or SIFT). A locus
was called a deleterious-allele locus if the minor
allele was considered deleterious. We compared
the ratio of deleterious alleles with the total
number of alleles at the deleterious-allele loci
genotyped between case children and compari-
son participants. For this analysis, we used both
the PolyPhen and SIFT determinations of what
alleles were deleterious. These summary vari-
ables were also analyzed using exact conditional
logistic regression for matched sets and were
calculated using SAS version 9.1.3.
In addition, for AOX1, SUOX and XDH,
we compared the distribution of groups of
variants that are inherited together on the
same chromosome (haplotypes). When con-
structing haplotypes, we considered only loci
for which the minor allele was not rare. For
AOX1, the 6-locus haplotypes using loci
78499A→G, 86558A→G (rs3731722),
87950T→G, 88099G→A (rs1050887),
88169A→delA, and 88248G→T were thus
considered. For SUOX we considered a
2-locus haplotype using loci –628G→A
(rs7297662) and –586T→A (rs773126). We
did not conduct haplotype analyses for XDH,
as all loci had rare minor alleles. The com-
mon gene variant is denoted as “0” and the
minor variant as “1”. For example, for SUOX,
the haplotype 10 corresponds to having the
minor variant at locus –628, A, and the com-
mon variant at locus –586, T. For each gene,
we tested the association between haplotypes
and disease status assuming a co-dominant
model for each haplotype with frequency
> 5% in the study population, using the
robust score test in CHAPLIN (Epstein and
Satten 2003; Satten and Epstein 2004; see
http://www.genetics.emory.edu/labs/
epstein/software/chaplin/index.html). For
each gene we also calculated the (marginal)
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Table 2. Coding/regulatory region polymorphism discovery results for aldehyde oxidase, sulfate oxidase, and xanthine dehydrogenase.
Gene Amino Minor allele Frequencies  Predicted protein phenotype
Polymorphisma position acid change  case group comparison groupb PolyPhenc SIFTd
AOX1 37630T→A Exon 17 I598N 0.050 (20) 0 (42) Probably damaging Not tolerated (0.02)
AOX1 67888A→G Exon 26 L957R 0.050 (20) 0 (48) Benign Tolerated (0.16)
AOX1 78499A→G Exon 30 N1135S 0.091 (22) 0.119 (42) Benign Tolerated (1.00)
AOX1 86558A→G Exon 34 H1297R 0.167 (12) 0.029 (34) Benign Tolerated (0.22)
AOX1 87950T→G 3´ UTR NA 0.063 (16) 0.053 (38) NA NA
AOX1 88099G→A 3´ UTR NA 0.056 (18) 0.043 (46) NA NA
AOX1 88169→delAT 3´ UTR NA 0.556 (18) 0.413 (46) NA NA
AOX1 88248G→T 3´ UTR NA 0.056 (18) 0.048 (42) NA NA
SUOX–628G→A 5´ UTR NA 0.773 (22) 0.396 (48) NA NA
SUOX –619G→A 5´ UTR NA 0.071 (14) 0 (46) NA NA
SUOX –586T→A 5´ UTR NA 0.357 (14) 0.435 (46) NA NA
SUOX –429T→C 5´ UTR NA 0 (14) 0.022 (46) NA NA
SUOX –317G→A 5´ UTR NA 0 (16) 0.018 (40) NA NA
SUOX 1642G→A Exon 6 E159L 0.056 (18) 0 (42) Benign Tolerated (0.15)
SOUX 1796C→T Exon 6 P210L 0 (18) 0.024 (42) Probably damaging Not tolerated (0.00)
XDH 26391G→A Exon 7 G172R 0 (20) 0.045 (44) Benign Not tolerated (0.05)
XDH 42390T→A Exon 17 N602L 0 (14) 0.029 (34) Probably damaging Not tolerated (0.02)
XDH 42404G→A Exon 17 R607Q 0 (14) 0.029 (34) Benign Not tolerated (0.04)
XDH 44269A→G Exon 18 I646V 0.046 (22) 0 (48) Benign Tolerated (0.64)
XDH 75118A→T Exon 34 I1238F 0 (18) 0.022 (46) Benign Tolerated (0.56)
NA, not applicable. 
aGenomic DNA position coordinates are relative to Start ATG codon for each gene. Variations present in NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/): AOX1 86558A→G
(rs3731722), AOX1 87950T→G (rs1050884),AOX1 88099G→A (rs1050887), AOX1 88169A→delAT (rs34427902), SUOX –628G→A (rs7297662), SUOX –586T→A (rs773126), SUOX
–317G→A(rs7963590), XDH 44269A→G (rs17323225). bThe number of sequenced chromosomes from the 11 case children and the 24 matched comparison children is in parentheses.
cPolyPhen prediction of functional effect of human nsSNPs ( http://genetics.bwh.harvard.edu/pph/). dSIFT values < 0.05 are predicted to be deleterious.
Table 3. Gene characteristics and minor allele frequencies for polymorphisms (excluding AOX1, SUOX,
and XDH).
Minor allele frequencya
Polymorphism Amino acid change Case group Comparison group
GSTP1 313A→G Ile→Val 0.25 (20) 0.36 (84)
MBL2 codon 54A→G Asp→Gly 0.23 (22) 0.21 (84)
ABCB1 3435C→T Synonymous 0.35 (20) 0.52 (84)
MTHFR 677C→T Ala→Val 0.41 (22) 0.40 (84)
NQO1 609C→T Pro→Ser 0.20 (20) 0.25 (84)
SLC19A1 80A→G His→Arg 0.45 (22) 0.48 (84)
SHMT1 1420C→T Leu→Phe 0.36 (22) 0.21 (84)
TPMT 460G→A Ala→Thr 0.00 (22) 0.06 (84)
TPMT 719A→G Tyr→Cys 0.00 (22) 0.06 (84)
VDR start codon FokI 0.40 (20) 0.42 (84)
TYMS 28-bp repeat 0.41 (22) 0.43 (84)
aThe number of sequenced chromosomes from the 11 case children and the 42 matched comparison children is in paren-
theses. Variations present in NCBI dbSNP database: TPMT 460G→A (rs1800460) and 719A→G (rs28933403), SLC19A1
80A→G (rs1051266), SHMT1 1420C→T (rs1979277), GSTP1 313A→G (rs1695), NQO1 609C→T (rs1800566), MBL2 codon
54A→G (rs1800450), ABCB1 3435C→T (rs1045642), MTHFR 677C→T (rs1801133), and the VDR start site polymorphism
(rs2228570).effect of each haplotype with frequency > 5%
on the odds of disease. For these univariate
analyses, we considered co-dominant, domi-
nant, and recessive models. 
We determined genotypes of available par-
ents of case children for each gene listed in
Table 3. We conducted transmission-disequi-
librium tests (TDTs) for linkage and associa-
tion. To include data from two case children
with only one available parent, we used the
1-TDT (Sun et al. 1999). 
Results
Case children (7 boys and 4 girls) ranged in 
age from 2 to 19 years at diagnosis and from 3
to 20 years at time of sample collection.
Characteristics of the leukemias of 11 case
children on which specimens were received are
presented in Table 1. The distribution of
immunophenotypes (T-cell vs. B-cell leukemia
determined by flow cytometry) among case
children was similar to what is seen in the gen-
eral population of children with ALL in the
United States (COG, personal communica-
tion). The TEL-AML1 translocation t(12;21),
found in about 25% of patients with ALL
(Romana et al. 1995), was identified in the
cells of two children between the ages of 2 and
10 years. Hyperdiploidy, another cytogenetic
aberration common in ALL, was found in cells
from a third child between the ages of 2 and
10 years. In all three instances, chromosomal
aberrations were found in association with
precursor B-cell ALL cases. The frequency of
cytogenetic chromosomal aberrations, such as
translocations and hyperdiploidy in this group
of leukemia cases, could not be compared with
the frequency of these aberrations found in the
general population of children with ALL
because, in most cases, bone marrow was not
stored, testing was not done, or cells did not
divide for metaphase analysis. 
Polymorphism discovery by DNA sequenc-
ing was performed to detect variant forms of
genes that code for enzymes inhibited by tung-
sten. A total of 125 variations in AOX1, 29
variations in SUOX, and 124 variations in
XDH were identiﬁed, of which 8 AOX1 loci, 7
SUOX loci, and 5 XDH loci were polymorphic
in our study population. Analysis was restricted
to polymorphisms in the coding regions of the
genes (cSNPs) that resulted in amino acid sub-
stitutions or those in potential regulatory
regions, including the promoter, exon/intron
boundaries, and 3´ UTR (Table 2). Minor
allele frequencies for all loci found to be poly-
morphic in our study population are listed in
Tables 2 and 3. 
We found no differences in frequencies of
minor alleles between case and comparison
participants for 10 genes that code for proteins
involved in the folate/purine biosynthesis
pathway, in xenobiotic metabolism, in cell dif-
ferentiation, or in innate immunity (Table 3).
Univariate logistic regression (Tables 4
and 5) identified only one locus (SUOX
–628G→A) that was significantly associated
with disease status (p=   0.007). All 11 case chil-
dren had at least one copy of the minor allele
(A); no child carrying a GG genotype had
leukemia. Fifty-ﬁve percent of the case children
and 25% of the comparison children were
homozygous for the minor allele (A). Forty-six
percent of the comparison children were
homozygous for the G allele. The proportion
of minor SUOX alleles also differed signifi-
cantly between case and comparison children
(p = 0.001); this proportion was not signifi-
cantly different for AOX1 or XDH. The pro-
portion of rare gene variants was borderline
signiﬁcantly different between case and com-
parison children for AOX1 (mid-p-value for
exact score was 0.06); this is because 2 of the
11 case children, but none of 24 comparison
children, had a rare AOX1 allele. No signiﬁcant
differences between rare allele frequencies in
case and comparison children were found for
XDH or SUOX. Further, the proportion of
deleterious alleles, as determined by the
PolyPhen and SIFT programs, was not signiﬁ-
cantly different between case and comparison
children (mid-p-values for exact score test were
0.58 for PolyPhen and 0.66 for SIFT). Finally,
the TDT revealed no locus in linkage or associ-
ation with a trait locus (Table 6). 
Aldehyde oxidase and sulﬁte oxidase haplo-
type analyses. The haplotypes estimated to
have non-zero frequency in the AOX1 and
SUOX genes calculated using the expectation–
maximization (EM) algorithm are given in
Table 7. Using the robust score test for haplo-
type effect, AOX1 had p = 0.38, based on 
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Table 4. Univariate matched conditional logistic regression analyses for SNP loci in AOXI, SUOX, and XDH.
95% CIb
Polymorphism Estimatea Lower Upper  p-Valuec
AOX1 37630T → A ∞ 0.05 ∞ 0.17
AOX1 67888A → G ∞ 0.05 ∞ 0.17
AOX1 78499A → G 0.43 0.01 6.15 0.46
AOX1 86558A → G ∞ 0.23 ∞ 0.17
AOX1 87950T → G 1.0 0.02 19.2 0.78
AOX1 88099G → A 1.14 0.02 22.1 0.78
AOX1 88196A → delAT 1.79 0.38 11.0 0.42
AOX1 88248G → T 1.14 0.02 22.1 0.78
SUOX –628G → A 6.81 1.28 257 0.007
SUOX –619G → A ∞ 0.05 ∞ 0.17
SUOX –586T → A 0.74 0.13 2.99 0.66
SUOX –429T → C 0 0 78.0 0.67
SUOX –317G → A— d —d —d —d
SUOX 1642G → A ∞ 0.03 ∞ 0.75
SUOX 1796C → T 0 0 117 0.63
XDH 26391G → A 0 0 13.1 0.33
XDH 42390T → A 0 0 78.0 0.67
XDH 42404G → A 0 0 78.0 0.67
XDH 44269A → G ∞ 0.05 ∞ 0.17
XDH 75118A → T 0 0 117 0.63
aPoint estimate of odds ratio of each copy of the minor allele on the odds of disease, obtained using matched conditional
logistic regression. Values of ∞ (0) correspond to loci where the case (comparison) children had at least as many copies
of the minor allele as the comparison (case) children in every informative stratum. bExact 95% CI values. cMid-P cor-
rected p-value for the score test. dFor the SUOX –317G→A locus, there were no informative matched sets (i.e., no
instances in which a case and at least one matched control had measured genotypes that were different).
Table 5. Univariate matched conditional logistic regression analyses for loci for all genes except AOX1,
SUOX and XDH.
95% CIb
Polymorphism Estimatea Lower Upper  p-Valuec
GSTP1 313A→G 0.56 0.15 1.68 0.30
MBL2 codon 54A→G 1.11 0.28 3.77 0.89
ABCB1 3435C→T 0.43 0.11 1.40 0.16
MTHFR 677C→T 1.05 0.35 3.31 0.90
NQO1 609C→T 0.75 0.17 2.63 0.68
SLC19A1 80A→G 0.91 0.30 2.71 0.90
SHMT1 1420C→T 1.95 0.64 6.87 0.17
TPMT 460G→A 0 0 4.36 0.43
TPMT 719A→G 0 0 4.36 0.43
VDR start codon FokI 0.93 0.26 2.97 0.90
TYMS 28-bp repeat 0.95 0.24 3.25 0.89
aPoint estimate of odds ratio of each copy of the minor allele on the odds of disease, obtained using matched conditional
logistic regression. Values of 0 correspond to loci where the comparison children had at least as many copies of the
minor allele as the case children in every informative stratum. bExact 95% CI values. cMid-P corrected p-value for the
score test.3 degrees of freedom (df ), and SUOX had p =
0.05, based on 3 df. We also examined indi-
vidual haplotype models for each haplotype
with a frequency of at least 5% in the study
population. For each haplotype, we compared
the null hypothesis that no haplotypes affect
the odds of disease with the alternative hypoth-
esis that the selected haplotype affects the odds
of disease. Note that results for the recessive
model may be unreliable because of the small
number of children having two copies of the
risk haplotype. Further, although AOX1 haplo-
type 100000 (G–A–T–G–A–G) also has a
nominally signiﬁcant p-value under a recessive
model, it has a protective effect. SUOX haplo-
type 10 (A–T) has a significant p-value for
both co-dominant and dominant models; the
ﬁrst position corresponds to the only locus sig-
niﬁcantly associated with case status in univari-
ate analyses (Table 4). SUOX haplotype 00
(A–T) is close to borderline signiﬁcant but pro-
tective for the co-dominant and recessive mod-
els. In general, the sign of the haplotype effect
in SUOX tracks the genotype at the ﬁrst locus,
suggesting this locus alone accounts for the
observed association.
Discussion
Investigators understood from the outset that
ﬁnding a cause of leukemia in this study was
unlikely because of the small number of case
children. Nonetheless, we decided to perform
genetic testing because the results from this
study may be useful in generating hypotheses
for subsequent leukemia clusters and because
of the possibility of performing meta-analysis
on data from this and subsequent studies to
elucidate causal mechanisms.
We studied two types of genetic informa-
tion: a) the cytogenetic and molecular changes
that are found in bone marrow cells from ALL
case children at diagnosis and b) the normal
genetic variations that occur in people that
might make some more susceptible than oth-
ers to the effects of environmental chemicals.
With regard to cytogenetic studies, no evi-
dence was found to suggest that a common
environmental exposure caused the leukemias,
although this possibility could not be ruled
out. Cytogenetic studies on pretreatment bone
marrow specimens suggested that the chromo-
somal aberrations and cell immunophenotypes
were present in approximately the same pro-
portion as in the general population of child-
hood ALL cases in the United States, although
this could not be conﬁrmed for chromosomal
aberrations because testing was not performed
in many cases and bone marrow was not stored
for later testing. 
For normal variation, we compared the
distributions of gene variants in case and com-
parison families for genes that code for four
groups of proteins: enzymes that are inhibited
by tungsten, folate pathway enzymes, proteins
involved in cell differentiation, and enzymes
that activate or detoxify carcinogens. We also
studied a gene variant in a protein involved in
innate immunity. 
Three mammalian enzymes—xanthine
dehydrogenase, sulfite oxidase, and aldehyde
oxidase—require molybdenum as a cofactor
(Garner and Stewart 2002). Tungsten readily
replaces molybdenum as a cofactor in these
enzymes, thus inactivating them (L’vov et al.
2002). Tungsten has also been shown to pre-
vent incorporation of molybdenum without
itself being incorporated into xanthine dehy-
drogenase. Sulﬁte oxidase has also been shown
to be inhibited by arsenite in vitro (Gardlik and
Rajagopalan 1991). Although it is not clear
how inhibition of these enzymes might affect
risk for leukemia, plausible mechanisms can be
hypothesized. For example, aldehyde oxidase
(probably identical to retinaldehyde oxidase)
irreversibly converts retinaldehyde to retinoic
acid, which mediates hematopoiesis and prog-
enitor cell differentiation through its effects on
Hox gene expression during embryogenesis
(Look 1997; Tocci et al. 1996). 
A comprehensive survey of the polymor-
phisms found in the coding and regulatory
regions of these three genes revealed only one
locus (SUOX –628) was signiﬁcantly associated
with disease status. If we adjusted for the
number of comparisons made in the univari-
ate logistic regression analyses, this locus
would no longer be signiﬁcant. However, the
pattern of genotypes is noteworthy (all chil-
dren with leukemia carried at least one copy of
the A allele; no child having the GG genotype
had leukemia). 
Sulﬁte oxidase is required for the physio-
logically essential oxidation of sulﬁte to sulfate,
the final step in the oxidative breakdown of
the amino acids cysteine and methionine.
Deﬁciency of sulﬁte oxidase due to mutations
in the human SUOX gene causes severe neuro-
logic deﬁcits resulting in death at an early age
or mental retardation [for a review, see Tan
et al. (2005)]. 
We found nothing in the scientiﬁc litera-
ture about the effect of the SUOX –628G→A
variant on sulﬁte oxidase activity. This poly-
morphism is in the 5´ UTR, between untrans-
lated exons and the first translated exon.
Although the physiologic consequences of poly-
morphisms in untranlsated regions remain to
be fully elucidated, these polymorphisms may
regulate gene expression through effects on
mRNA stability, localization, and translational
efﬁciency (Gebauer and Hentze 2004). If this
variant were to express less sulfite oxidase
Steinberg et al.
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Table 6. Transmission disequilibrium analysis.
Children with only one 
p-Value Intact trios available parent (dyads)
Standard TDTa 1-TDTb Bc Cd De Ef
GSTP1 313A→G 1.0 0.65 2 2 0 1
MBL2 codon 54A→G 0.71 0.71 3 4 0 0
ABCB1 3435C→T 0.26 0.26 2 5 0 0
MTHFR 677C→T 0.32 0.21 6 3 1 0
NQO1 609C→T 0.65 0.65 2 3 0 0
SLC19A1 80A→G 0.26 0.74 5 2 0 2
SHMT1 1420C→T 0.48 0.74 3 5 1 0
TPMT 460G→A 0.32 0.32 0 1 0 0
TPMT 719A→G 0.16 0.16 0 2 0 0
VDR start codon FokI 0.26 0.48 5 2 0 1
TYMS 28-bp repeat 0.48 0.21 3 5 0 2
aStandard TDT is (B – C)2/(B + C). b1-TDT including data from trios and dyads is (B + D – C – E)2/ (B + D + C + E)*. cNumber
of times a heterozygous parent transmitted the minor allele. dNumber of times a heterozygous parent transmitted the
major allele. eNumber of times the case child had more minor alleles than the available parent. fNumber of times the case
child had fewer minor alleles than the available parent.
Table 7. Hapotype analysis for common SNP loci in AOX1aand SUOXb.
β (p-value) for model
Haplotpye Frequency Co-dominant Dominant Recessive
AOX1a
000000 (A–A–T–G–A–G) 0.38 –0.59 (0.25) –0.35 (0.74) –∞ (0.02)
000010 (A–A–T–G–delA–G) 0.46 0.64 (0.20) 1.50 (0.09) 0.21 (0.82)
011101 (A–G–G–A–A–T) 0.05 0.16 (0.09) 0.20 (0.88) –∞ (0.39)
100000 (G–A–T–G–A–G) 0.09 –1.94 (0.17) –2.10 (0.18)  –∞ (0.19)
110000 (G–G–T–G–A–G) 0.02 —b —b —b
SUOX
00 (G–T)c 0.29 –1.42 (0.05) –1.50 (0.11) –∞ (0.05)
01 (G–A) 0.19 –1.56 (0.07) –1.67 (0.10) –∞ (0.12)
10 (A–T) 0.29 1.63 (0.02)  2.61 (0.01) 1.61 (0.32)
11 (A–A) 0.23 0.80 (0.23) 1.24 (0.18) –0.93 (0.86)
aAOX1 alleles with minor allele frequency of > 0.05 create a six maker haplotype of 78499A→G, 86558A→G, 87950T→G,
88099G→A, 88169A→delA and 88248G→T. bAnalysis not performed because the haplotype was too infrequent. cSUOX
alleles with minor allele frequency of > 0.05 form a two marker haplotype of –628G→A and –586T→A.protein or code for an enzyme with decreased
sulﬁte oxidase activity, it is possible that expo-
sure to tungsten, arsenic, or both could further
decrease activity, thus creating a situation
wherein people are vulnerable to adverse effects
of decreased sulﬁte oxidase activity. Many of
the comparison children living in Churchill
County had this gene variant as well as tung-
sten and arsenic exposure but did not develop
leukemia. For this reason, we think that expo-
sure to additional chemicals would be required
to cause adverse health effects.
Whether and how the SUOX –628 locus
genotype in the 5´ UTR might affect the avail-
ability of sulﬁte oxidase need to be studied fur-
ther. At this point, we have no evidence to
suggest that any genotype at this locus of
SUOX affects the concentration or activity of
sulﬁte oxidase. Population stratiﬁcation (case
and comparison groups coming from geneti-
cally diverse populations thereby showing spu-
rious associations) probably does not explain
the ﬁnding of an association at the –628 locus
with disease status because 95% of case and
comparison children identiﬁed as white, with
the two groups having similar ethnicity.
Because of the large number of comparisons
made, there are several possible explanations
for these associations. They may be because of
chance alone; alternatively, carrying the GG
genotype may be protective or carrying an A
allele may increase risk. Last, the locus we
found to be associated with disease status may
be in linkage disequilibrium with another
unrelated locus. Although the finding of an
association is interesting and warrants further
research, the genotype at the SUOX –628
locus is currently not predictive of any clinical
outcome nor does it have any known use in
clinical care.
Regarding tungsten mutagenicity, in a
study by Miller et al. (2001), exposure of a
nontumorigenic, human osteoblast-like cell
line to heavy metal–tungsten alloys, dense
heavy metal composite materials comprising
tungsten (91–93%), nickel (3–5%), and either
cobalt or iron (2–4%) resulted in a signiﬁcant
increase in transformation frequency (8.9- ±
0.93-fold). The mechanism for transformation
appeared to be increased DNA breakage or
chromosomal aberrations. However, tungsten
alone did not cause DNA breaks in these cells. 
Although the National Toxicology
Program (NTP) found no evidence from a lit-
erature review that tungsten is carcinogenic
(NTP 2003), it is now studying short-, inter-
mediate-, and long-term exposure effects of
tungsten using a variety of toxicologic end
points including carcinogenicity. Rats and
mice of both sexes will be exposed to sodium
tungstate dihydrate in their drinking water for
periods ranging from 2 weeks to 2 years.
Despite the lack of evidence in the literature,
the ability of tungsten to inhibit three
enzymes that may affect hematopoiesis or
detoxiﬁcation could conceivably alter risk for
mutations or chromosomal aberrations. 
In previous studies, rats fed high tungsten
and molybdenum-free diets were XDH-
deﬁcient, which inhibits conversion of purines
to uric acid. Because imbalances among
deoxynucleotide pools have been linked to
mutagenesis, it is plausible that tungsten-
induced derangements in purines could be
involved in leukemogenesis (James et al. 1994;
Kunz and Kohalmi 1991). 
Other studies have shown that molybde-
num-deﬁcient rats fed tungsten had decreased
sulﬁte oxidase and xanthine oxidase activities.
Although these rats appeared healthy, they
were more susceptible than control rats to
bisulﬁte toxicity. The lethal dose for intraperi-
toneal bisulfite was approximately 2.6 times
lower for the tungsten-treated animals
(Cohen et al. 1973). Sulfite oxidase is also
inactivated by arsenite, although by a mecha-
nism different than tungsten inactivation.
Arsenite binds to sulfhydryl groups of molyb-
dopterin and in doing so ultimately displaces
molybdenum (Gardlik et al. 1991).
Case and comparison specimens were also
genotyped for polymorphic forms of genes that
code for enzymes in the folate/purine biosyn-
thesis pathway. The folate pathway is essential
to single-carbon metabolism, which is critical in
DNA synthesis and repair, regulation of gene
expression, and protein and polyamine synthe-
sis (Smith et al. 2005). We studied polymor-
phic forms of folate/purine pathway enzymes
including MTHFR, TYMS, SLC19A1, TPMT,
and SHMT1 and found no differences in distri-
bution of polymorphisms between case and
comparison families. However, Skibola et al.
(1999) found a signiﬁcant association between
two polymorphic forms of MTHFR, including
the 677C→T polymorphism, and decreased
risk for ALL. Skibola et al. (2002) also reported
that two other polymorphic genes in the folate
pathway conferred decreased risk for ALL: the
5´ UTR polymorphism of TYMS and the
1420C→T polymorphism of SHMT1. An
association between the 677C→T substitution
in MTHFR and hyperdiploidy, a common
cytogenetic aberration in childhood ALL, has
also been demonstrated (Pui et al, 2004). 
Finally, we genotyped specimens to deter-
mine the relative frequencies of polymorphic
forms of the gene coding for the carcinogen-
metabolizing enzyme NQO1 (EC1.6.992).
NQO1 protects against oxidative stress by cat-
alyzing the two-electron reduction of quinones
to hydroquinones. The 609C→T polymor-
phism codes for an enzyme with low activity
and has been associated with increased risk for
ALL in children (relative risk, 1.7; 95% CI,
1.2–2.4) (Krajinovic et al. 2002). Frequencies
of the high-risk polymorphism were not
significantly different between Churchill
County case and comparison children. Our
failure to replicate results from previous stud-
ies of genetic polymorphisms associated with
ALL might be because of the small size of our
study population, false positive ﬁndings in the
original studies (type 1 error), or differences
among the genetic make up of the background
populations sampled in this and other studies. 
Although childhood leukemia has a shorter
latency than most solid tumors occurring later
in life, exposures that can no longer be docu-
mented may have occurred years before the
disease was manifested. In the case of leukemia,
in utero exposures are especially important.
Cytogenetic translocations and hyperdiploidy
noted in diagnostic bone marrow cells of chil-
dren with leukemia have been found in the
children’s neonatal blood spots, thus indicating
that they are induced in utero (McHale and
Smith 2004). Latency periods have been
noted, in some cases, to exceed 10 years. The
mechanism for generation of most of the
translocations has been suggested to be aber-
rant repair following abortive apoptosis rather
than V(D)J recombination or exposure to
topoisomerase II inhibitors (McHale and
Smith 2004). 
The environmental and genetic factors that
we focus on in this article, the SUOX –628
locus and exposure to tungsten and arsenic,
were present before an increase of incidence of
childhood ALL was reported and continued to
be present after leukemias were no longer
occurring at an elevated rate, thus weakening
the case for their having a role in causality. As a
result of this investigation, water treatment has
been improved and exposure to tungsten and
arsenic reduced, although any effects of remov-
ing these chemicals have not had time to be
manifested. 
Conclusions
From the information obtained in this study
and in consultation with members of the
COG, limited conclusions can be drawn. The
distribution of types of leukemia in Churchill
County (for example, the ratio of pre-B-cell to
T-cell leukemias and the ratio of standard-risk
to high-risk cases) is what one would expect in
comparison to the larger population of
leukemias studied by the COG in the United
States. Although genetic studies did not provide
evidence that a common agent or genetic sus-
ceptibility factor had caused the leukemias, the
association between the SUOX –628 genotype
and ALL, possibly interacting with high tung-
sten or arsenic levels, warrants further investiga-
tion. We are studying the prevalence of these
variants in a larger population of children with
ALL. We assume that there was no major
change in the prevalence of alleles or exposure
in the Churchill County population in the
years preceding this investigation. We cannot
rule out the possibility that exposures not
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accounted for in this investigation might have
been associated with cases of leukemia either in
conjunction with the documented exposures or
unrelated to them; however, the ﬁndings of this
study and those of Rubin et al. (2007) do not
support an association of the known exposures
with the temporal increase in the incidence of
leukemia in Churchill County, Nevada.
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